New price targets, capital raises and 100% stock return (week 50)

Nordic | Biotech & Healthcare Your insights to listed Danish & Nordic biotech & healthcare stocks. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. We also present the top 3 best-performing stocks in the Nordics each week.

In the past week, Genmab received new price targets, Pila Pharma announced outcome of their rights issue, Fluoguide raised 12 MSEK, and 2CureX got an ethical approval to start a clincal trial using IndiTreat. Notably, a Danish biotech stock rose nearly 100%.

6 of the 20 listed Danish biotech companies published news. 11 of the 20 companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Cessatech continues to be the best performing stock year-to-date with a 148% increase.

Do you want to stay tuned to the developments of impact companies and stocks in the Nordics? We have launched a blog and newsletter that dives into impact stocks listed in the Nordics. The newsletter help you to invest more sustainably in the businesses of tomorrow, track the development of multiple sectors including energy production, waste management, and carbon capture. We follow the more than100 large, medium and small cap impact companies in the Nordics.

Danish Company news the past week

Ascendis Pharma

No news the past week


No news the past week


No news the past week

CS Medica

No news the past week


No news the past week

Evaxion Biotech

No news the past week


No news the past week


FluoGuide raises SEK 12 million through exercise of warrants (Link)


JP Morgan lowered their price target from 3,200 DKK to 2,500 DKK, while UBS raised their price target from neutral to buy with a price target of 2,800 DKK.

Capital Increase in Genmab as a Result of Employee Warrant Exercise (Link)


No news the past week

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

Pila Pharma AB announces outcome of the rights issue (Link)


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week


ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 (Link)

Zealand Pharma

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (Link)

Y-mAbs Therapeutics

No news the past week


2cureX Receives Ethical Approval for Groundbreaking HIPEC Clinical Trial (Link)



On average, the Danish biotech and healthcare stocks delivered a positive share price performance last week of 7.3%. The performance was driven by Expres2ion Biotech which rose 96%. Expres2ion did not report any news. However, the increase is most likely driven by the EU grant of 8 MEUR corresponding to 90 MSEK they received two weeks ago, raising the stock 46%. The Pila Pharma stocl also did very well despite news of their rights issue only being subscribed by 31% corresponding to 8.1 MSEK. FluoGuide had a 10% increase following a 12 MSEK capital raise through exercise of warrants. The best stocks year-to-date are Curasight, Fluoguide, Zealand Pharma, Cessatech and Saniona with 77-148% performances. However, overall the Danish biotech and healthcare stocks are in negative territory this year with a year-to-date return of -1,1%.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date and last twelve months

Nordic biotech and healthcare developments (KPHC-index)

The past week, the Kapital Partner Nordic Healthcare Index (KPHC) rose 1.9% to 62.8 and the index thus continues small improvements after hitting the all-time low in October. The Kapital Partner Nordic Healthcare Index tracks all biotech & healthcare companies in the Nordics, including large-cap companies such as Novo Nordisk and Genmab and smaller companies such as Curasight. In the past 12 months, it has significantly underperformed relative to the C25-index in Copenhagen and the S30-index in Stockholm, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC-index’s downward trajectory.

The index development for Kapital Partner Healthcare Index the past 12 months

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

53-96% in weekly retrun for the three best performing Nordic biotech & healthcare stocks the past week

Expres2ion Biotech Holding AB (96%) (Nordnet) is a research and development-based company with a patented platform in biotech protein production. The company has its own development pipeline of vaccine candidates for COVID-19, breast cancer, influenza, and malaria. In addition, the company generates revenue from the sale of manufacturing services and platform licenses. Prior to last week, Expres2ion received a 8 MEUR grant for the development of a vaccine against Nipah virus (read more).

Qlife Holding AB (88%) (Nordnet) specializes in the research and development of IVD units. The units are used as biomarker tests in blood and are used as a complement to other tests in healthcare. Cooperation is also carried out with other actors on the market. Last week, Qlife Holding reached an agreement with Hipro Biotechnology in a deal worth potentially up to 500 MSEK (Read more).

QuiaPEG Pharmaceuticals Holding AB (53%) (Nordnet)  operates in medical technology. The company has developed a technological platform that is used to develop existing pharmaceuticals. The technology is based on what is known as PEGylation, a technique that connects water-soluble polymers with the pharmaceuticals and is used to improve various characteristics in the biopharmaceuticals in regards to stability and resistance.

Sources: Refinitiv & Nordnet


Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.


Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email.